The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model
Open accessAbstract
Inflammation is a key pathological hallmark of Alzheimer’s disease (AD), although its impact on disease progression and neurodegeneration remains an area of active investigation. Among numerous inflammatory cytokines associated with AD, IL-1β in particular has been implicated in playing a pathogenic role. In this study, we sought to investigate whether inhibition of IL-1β signaling provides disease-modifying benefits in an AD mouse model and, if so, by what molecular mechanisms. We report that chronic dosing of 3xTg-AD mice with an IL-1R blocking Ab significantly alters brain inflammatory responses, alleviates cognitive deficits, markedly attenuates tau pathology, and partly reduces certain fibrillar and oligomeric forms of amyloid-β. Alterations in inflammatory responses correspond to reduced NF-κB activity. Furthermore, inhibition of IL-1 signaling reduces the activity of several tau kinases in the brain, including cdk5/p25, GSK-3β, and p38–MAPK, and also reduces phosphorylated tau levels. We also detected a reduction in the astrocyte-derived cytokine, S100B, and in the extent of neuronal Wnt/β-catenin signaling in 3xTg-AD brains, and provided in vitro evidence that these changes may, in part, provide a mechanistic link between IL-1 signaling and GSK-3β activation. Taken together, our results suggest that the IL-1 signaling cascade may be involved in one of the key disease mechanisms for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence suggests that the pathological activation of glial cells and the release of inflammatory factors involved in neuroinflammation can exacerbate tau pathology via direct or indirect pathways, leading to neuronal damage and cognitive impairment, ultimately aggravating AD pathology [113, 114].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [113]
In the citing paper
“First, the proinflammatory cytokines TNFα, IL1 β, and IL6 have been shown to promote tau phosphorylation in neurons (Bhaskar et al., 2010; Kitazawa et al., 2011; Quintanilla et al., 2004).”
From Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease (2018) · cites this paper as Kitazawa et al., 2011
In the citing paper
“IL-1 receptor signalling is found to play a key role in neuroinflammation-induced tau phosphorylation by enhancing the activity of tau kinases including cyclin-dependent-like kinase 5/p25 (CDK5/p25), glycogen synthase kinase 3β (GSK3β), and p38 mitogen-activated protein kinase (p38-MAPK)60,61.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“For example, aging itself triggers differential activation in microglia isolated from the APP/PS1 transgenic mouse model (54, 67).”
BackgroundGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Lucas, J. J., Hernández, F., Gómez‐Ramos, P., Morán, M. A., Hen, R., & Avila, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 913
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease
Blurton-Jones, M. M., Kitazawa, M., Martínez‐Coria, H., Castello, N. A., Müller, F.-J., Loring, J. F., Yamasaki, T. R., Poon, W. W., Green, K. N., & LaFerla, F. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901402106 · Cited by 869
Self-citationImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Lee, S. C., Liu, W., Dickson, D. W., Brosnan, C., & Berman, J. (1993) · Journal of Immunology · doi:10.4049/jimmunol.150.7.2659 · Cited by 850
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
Self-citationRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 4×
“We and others (25, 32, 53) previously demonstrated that altered inflammation in the brain significantly influenced the subsequent development of tau pathology, independent of Ab pathology, in the 3xTg-AD mice and other mouse models.”
BackgroundMethodInfluentialMonoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Li, Y., Liu, L., Barger, S. W., & Griffin, W. S. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01605.2003 · Cited by 563
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
Zhang, Z., Hartmann, H., Do, V. M., Abramowski, D., Sturchler, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H. C., Säftig, P., et al. (1998) · Nature · doi:10.1038/27208 · Cited by 515
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433
Reversible memory loss in a mouse transgenic model of Alzheimer’s disease
Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420
Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., Casadei, V. M., & Grimaldi, L. M. E. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00226-x · Cited by 400
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 2×
“For example, aging itself triggers differential activation in microglia isolated from the APP/PS1 transgenic mouse model (54, 67).”
BackgroundMethodChakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D. H., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 302
Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 298
Self-citationAdjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
Cribbs, D. H. (2003) · International Immunology · doi:10.1093/intimm/dxg049 · Cited by 283
Self-citationMcAlpine, F. E., Lee, J., Harms, A. S., Ruhn, K. A., Blurton-Jones, M. M., Hong, J. J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.006 · Cited by 274
Self-citationSheng, J. G., Ito, K., Skinner, R. D., Mrak, R. E., Rovnaghi, C. R., van Eldik, L. J., & Griffin, W. S. T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00104-2 · Cited by 269
Forloni, G., Demicheli, F., Giorgi, S., Bendotti, C., & Angeretti, N. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90202-m · Cited by 257
Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 254
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
Tobinick, E. L., & Gross, H. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-2 · Cited by 250
Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production
Kim, S. H., Smith, C. J., & Eldik, L. J. V. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00126-x · Cited by 241
The ups and downs of Wnt signaling in prevalent neurological disorders
Ferrari, G. V. D., & Moon, R. T. (2006) · Oncogene · doi:10.1038/sj.onc.1210064 · Cited by 227
Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic Mice
Martínez‐Coria, H., Green, K. N., Billings, L. M., Kitazawa, M., Albrecht, M., Rammes, G., Parsons, C. G., Gupta, S., Banerjee, P., & LaFerla, F. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090452 · Cited by 224
Self-citationIncreased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment
Forlenza, O. V., Diniz, B. S., Talib, L. L., Mendonça, V. A., Ojopi, E. P. B., Gattaz, W. F., & Teixeira, A. L. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000255051 · Cited by 218
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice
Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., Obregon, D., Flavell, R. A., & Mullan, M. J. (2002) · Nature Neuroscience · doi:10.1038/nn968 · Cited by 217
Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease
Peskind, E. R., Griffin, W. S. T., Akama, K. T., Raskind, M. A., & Eldik, L. J. V. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00048-1 · Cited by 215
Mori, T., Koyama, N., Arendash, G. W., Horikoshi‐Sakuraba, Y., Tan, J., & Town, T. (2009) · Glia · doi:10.1002/glia.20924 · Cited by 212
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Levites, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25410 · Cited by 209
Chakrabarty, P., Ceballos-Diaz, C., Beccard, A., Janus, C., Dickson, D., Golde, T. E., & Das, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903382 · Cited by 206
Inflammatory changes parallel the early stages of Alzheimer disease
Parachikova, A., Agadjanyan, M. G., Cribbs, D. H., Blurton-Jones, M., Perreau, V., Rogers, J., Beach, T. G., & Cotman, C. W. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.08.014 · Cited by 203
Self-citationToll-Like Receptors in Alzheimer's Disease
Landreth, G. E., & Reed-Geaghan, E. G. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-00549-7_8 · Cited by 180
Sheng, J. G., Jones, R. A., Zhou, X. Q., McGinness, J. M., Van Eldik, L. J., Mrak, R. E., & Griffin, W. S. T. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00041-9 · Cited by 176
S100β Stimulates Inducible Nitric Oxide Synthase Activity and mRNA Levels in Rat Cortical Astrocytes
Hu, J., Castets, F., Guevara, J. L., & Van Eldik, L. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2543 · Cited by 173
Basu, A., Krady, J. K., O’Malley, M. E., Styren, S. D., DeKosky, S. T., & Levison, S. W. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-14-06071.2002 · Cited by 170
Cacabelos, R., Barquero, M. S., Garcia, P. E., Alvarez, X. A., & de Seijas, E. V. (1991) · PubMed · Cited by 148
Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0664-05.2005 · Cited by 147
Interleukin-1 Promotes Expression and Phosphorylation of Neurofilament and tau Proteins in Vivo
Sheng, J. G., Zhu, S., Jones, R. A., Griffin, W. S. T., & Mrak, R. E. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7393 · Cited by 147
GSK-3 and the neurodevelopmental hypothesis of schizophrenia
Kozlovsky, N., Belmaker, R. H., & Agam, G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00131-6 · Cited by 128
Interruption of β-Catenin Signaling Reduces Neurogenesis in Alzheimer's Disease
He, P., & Shen, Y. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0421-09.2009 · Cited by 126
Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., & Ferrero, P. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0562-6 · Cited by 125
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Localization of Interleukin 1 Type I Receptor mRNA in Rat Brain
Wong, M., & Licinio, J. (2006) · NeuroImmunoModulation · doi:10.1159/000097143 · Cited by 118
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease
Petzold, A., Jenkins, R., Watt, H., Green, A. J. E., Thompson, E. J., Keir, G., Fox, N. C., & Rossor, M. N. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01257-0 · Cited by 115
S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons
Li, Y., Barger, S. W., Liu, L., Mrak, R. E., & Griffin, W. S. T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740143.x · Cited by 115
S100β Increases Levels of β‐Amyloid Precursor Protein and Its Encoding mRNA in Rat Neuronal Cultures
Li, Y., Wang, J., Sheng, J. G., Liu, L., Barger, S. W., Jones, R. A., Eldik, L. J. V., Mrak, R. E., & Griffin, W. S. T. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041421.x · Cited by 109
Weeraratna, A. T., Kalehua, A. N., DeLeon, I., Bertak, D., Maher, G., Wade, M. S., Lustig, A., Becker, K. G., Wood, W. W., Walker, D. G., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.10.028 · Cited by 109
Head, E., Pop, V., Vasilevko, V., Hill, M., Saing, T., Sarsoza, F. M., Nistor, M., Christie, L., Milton, S. C. F., Glabe, C. G., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0208-08.2008 · Cited by 107
Self-citationLiu, L., Li, Y., Eldik, L. J. V., Griffin, W. S. T., & Barger, S. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02909.x · Cited by 105
Esposito, G., Scuderi, C., Lu, J., Savani, C., Filippis, D. D., Iuvone, T., Steardo, L., Jr., Sheen, V. L., & Steardo, L. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00159.x · Cited by 97
Tachida, Y., Nakagawa, K., Saito, T., Saido, T. C., Honda, T., Saito, Y., Murayama, S., Endo, T., Sakaguchi, G., Kato, A., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05127.x · Cited by 86
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β
Kitazawa, M., Trinh, D. N., & LaFerla, F. M. (2008) · Annals of Neurology · doi:10.1002/ana.21325 · Cited by 82
Self-citationSheng, J. G., Mrak, R. E., Bales, K. R., Cordell, B., Paul, S. M., Jones, R. A., Woodward, S., Zhou, X. Q., McGinness, J. M., & Griffin, W. S. T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740295.x · Cited by 82
de Souza, D. F., Leite, M. C., Quincozes‐Santos, A., Nardin, P., Tortorelli, L. S., Rigo, M., Gottfried, C., Leal, R. B., & Gonçalves, C. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.10.012 · Cited by 67
Yang, Y., Quitschke, W. W., & Brewer, G. J. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00164-8 · Cited by 62
Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism
Giuliani, F., Vernay, A., Leuba, G., & Schenk, F. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.009 · Cited by 49
Langmann, T., Mauerer, R., & Schmitz, G. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059774 · Cited by 49
Regulation of the S100B gene by α1-adrenergic stimulation in cardiac myocytes
Tsoporis, J. N., Marks, A., Eldik, L. J. V., O'Hanlon, D., & Parker, T. G. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00161.2002 · Cited by 28
Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes
Tanji, K., Mori, F., Imaizumi, T., Yoshida, H., Satoh, K., & Wakabayashi, K. (2003) · Neuroreport · doi:10.1097/00001756-200303030-00023 · Cited by 19
Flagged first, then by citations
Cited by
Sorted by citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Compromised MAPK signaling in human diseases: an update
Kim, E., & Choi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,033
Cytokine networks in neuroinflammation
Becher, B., Spath, S., & Goverman, J. M. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.123 · Cited by 707
Metadata
- Authors
- Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M.
- Affiliations
- University of California, Irvine (US)
- Roche Pharmaceuticals , Palo Alto, CA 94304
- Corresponding author
- Kitazawa, Masashi
- Cheng, David
- Vasilevko, Vitaly
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12
- Volume
- 187
- Issue
- 12
- Pages
- 6539-6549
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC4072218
- OpenAlex
- W2129470375
- Cited by
- 473
- References
- 83
- Citations by year
- 2026: 32 · 2025: 42 · 2024: 40 · 2023: 36 · 2022: 43 · 2021: 35 · 2020: 46 · 2019: 31 · 2018: 39 · 2017: 26 · 2016: 30 · 2015: 18 · 2014: 24 · 2013: 17 · 2012: 14
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4r01ag020241-15)
- National Institute on Aging (P01AG000538, R01AG020335, P50 AG 16573, R01 AG-020241, AG020241, AG 00538, P50AG016573, RF1AG020241, R01AG20335, R01AG021982)
- National Institute of Neurological Disorders and Stroke (NS 050895, R01NS050895)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K99AR054695)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, IL-1β signaling, IL-1 receptor blockade, tau pathology, cognitive impairment, amyloid-beta, NF-κB, tau kinases, GSK3β, CDK5/p25, p38 MAPK, Wnt/β-catenin signaling, S100B, astrocytes, neuroinflammation, 3xTg-AD mice, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Cells, Cultured, Cognition Disorders, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Nerve Growth Factors, S100 Proteins, Neurons, Signal Transduction, NF-kappa B, tau Proteins, Receptors, Interleukin-1, Cell Line, Tumor, beta Catenin, Mice, Interleukin-1beta, S100 Calcium Binding Protein beta Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
